Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-encoded trispecific CD19xBCMAxCD3 T cell engager
- Development stage
- Unknown
- Lead developer
- METiS TechBio
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
An mRNA-encoded trispecific T-cell engager (TCE) designed to target CD19, BCMA, and CD3. Developed by METiS TechBio, this therapeutic utilizes an optimized mRNA sequence formulated in a novel lipid nanoparticle (LNP) to induce broad depletion of B cells and plasma cells. The construct consists of a CD3-binding scFv fused with VHH domains specific for CD19 and BCMA. It is intended for the treatment of B-cell-driven cancers, such as multiple myeloma, and autoimmune diseases like systemic lupus erythematosus (SLE). Preclinical data suggests potent B-cell killing and a favorable safety profile with reduced cytokine release compared to traditional protein-based engagers, particularly when administered subcutaneously. The LNP delivery system is designed for preferential biodistribution to secondary lymphoid organs, including the spleen, bone marrow, and lymph nodes.
- Other names
- CD19xBCMAxCD3 mRNA-TCECD-19xBCMAxCD3 mRNA-TCECD 19xBCMAxCD3 mRNA-TCEtrispecific CD19xBCMAxCD3 T cell engager
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on mRNA-encoded trispecific CD19xBCMAxCD3 T cell engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-encoded trispecific CD19xBCMAxCD3 T cell engager.